AstraZeneca is first to win EU approval for an inhaled 4-in-1 flu vaccine

AstraZeneca ($AZN) has gotten EU approval for its inhaled, four-in-one flu vaccine for children. Fluenz Tetra is among a new generation of treatments that are expected to carry premium prices and so boost the revenues companies will generate from a part of the market once considered a backwater.

The U.K. company's new vaccine is approved for children and adolescents from 24 months up to 18 years of age. It has the further advantage of being the first intra-nasal four-strain influenza vaccine available in Europe that doctors can turn to for use in children afraid to be vaccinated by needles. AstraZeneca said Fluenz Tetra will replace its Fluenz three-strain (trivalent) live attenuated influenza vaccine starting with the 2014-2015 flu season. The vaccine, marketed in the U.S. as FluMist Quadrivalent, was approved by the FDA in 2012 for ages 2 to 49.

Historically, seasonal flu vaccines have contained two influenza A viruses and one influenza B virus. The newer vaccines carry a second influenza B strain. AstraZeneca says that in the last 10 years, the second B virus has accounted for 25% of the strains circulating in Europe.

With the added protection comes higher pricing. Vaccine partners Sanofi ($SNY) and Merck ($MRK), the largest vaccine makers globally, expect their new four-strain shot to price at least 50% higher than with its three-strain vaccines. Analysts have forecast sales of the new shot to bring in $384 million annually by 2022. GlaxoSmithKline ($GSK) is selling its new quadrivalent Fluarix to the U.S. Centers for Disease Control and Prevention (CDC) for $12.03 per dose, a 50% premium over its three-strain vaccine. Analysts think it will take a few years for the four-strain vaccines to become the standard. When they do, they project the market will grow more than 5% a year, rather than in the lower single digits.  

- here's the announcement

Special Reports: Top 10 Best-Selling Flu Vaccines of 2012 | Top 5 Vaccine Companies by 2012 Revenue - Sanofi - GSK

Related Articles:
GSK, Sanofi, AstraZeneca ready to roll out premium-priced flu vaccines
AstraZeneca's FluMist Quadrivalent to hit U.S. market 
FDA approval expands GSK's franchise of flu vaccines
Sanofi joins GSK, MedImmune with 4-in-1 flu vaccine
Sales upside for Sanofi's Fluzone Quadrivalent looks strong

Suggested Articles

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.